14.10.2022
"Novel Epigenetic Targets in Pediatric Brain Tumors"
***Deutsche Version unten*** | *** Versão em português abaixo***
The next webinar from the program Tübingen Science Bridge – Brazil will take place on November 9 at 11:30 am BRT (03:30 pm MEZ) and will focus on the area of Health Sciences. The lecture has the participation of Prof. Dr. Rafael Roesler, Federal University of Rio Grande do Sul - Department of Pharmacology, Institute for Basic Health Sciences, and Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA). He will put on the agenda the theme "Novel Epigenetic Targets in Pediatric Brain Tumors".
The Baden-Württemberg Center for Brazil and Latin America at the Universität Tübingen is expanding the successful Tübingen Science Bridge - Brazil, which started in April 2022 in cooperation with partner universities in Brazil, to other countries in Latin America. The expansion initially includes Tübingen's partner universities in Argentina, Chile, Peru, Colombia, and Mexico. As of now, the program will be also called Tübingen Science Bridge - Latin America.
As before, the program aims to contribute to the internationalization of science and research. Scientists from several partner institutions will present their latest research data, promoting an integrated and constructive environment for scientific interaction and also contributing global knowledge.
The lectures of the Tübingen Science Bridge are aimed at professors and scientific researchers, graduate students, as well as a more the general audience. The online seminar will be held in English on the ZOOM platform in order to allow discussion and interaction.
Webinars will be held in English on the ZOOM platform in order to allow discussion and interaction.
Register link: https://bit.ly/TSB-november
Lecture Briefing:
Epigenetic reprogramming is a feature of brain cancers that arise during childhood. Medulloblastoma (MB), a malignant brain tumor that afflicts mostly children and adolescents, presents four distinct molecular subgroups, namely WNT, SHH, Group 3 and Group 4. Components of the epigenetic machinery that play a role in normal embryonic development and can be hijacked by pediatric tumors include histone methyltransferases (HMTs) and histone deacetylases (HDACs). Overexpression of the HMT G9a (euchromatic histone lysine methyltransferase 2, EHMT2) is seen in several cancer types, and ZEB1 is a transcription factor that participates in cerebellar development and cooperates with HDACs and micro RNAs, thus contributing to epigenetic regulation. We show that expression of the G9a/Ehmt2 gene is higher in MB tumors belonging to SHH, Group 3, and Group 4 subgroups. Higher G9a expression was significantly associated with shorter overall survival in patients with MB. In cellular experiments, G9a inhibition reduced MB cell viability. Increased expression of ZEB1 was found in MB tumors compared to normal cerebellar tissue. Expression was higher in the SHH subgroup compared to all other MB subgroups. Higher ZEB1 expression was associated with poor prognosis in Group 3 and Group 4 MB. Treatment with the immunomodulator and HDAC inhibitor fingolimod (FTY720) reduced ZEB1 expression in MB cells representative of Group 3 and Group 4 MB. Our findings indicate that 1) higher transcription of G9a may predict poor prognosis in patients with SHH MB; 2) inhibiting G9a can induce antitumor effects in MB; 3) there are subgroup-specific associations of ZEB1 expression with prognosis of patients with MB; and 4) ZEB1 expression can be reduced by HDAC inhibition. Together, these results reveal G9a/EHMT2 and ZEB1 as epigenetic regulators that might be novel potential prognostic biomarkers and therapeutic targets in MB.
More information about the Tübingen Science Bridge (agenda, lectures, links for registration):https://bit.ly/TSB-Agenda2022
*** Versão em português ***
O próximo evento on-line do programa Tübingen Science Bridge - Brazil acontecerá no dia 09 de novembro às 11:30 am BRT (03:30 pm MEZ), tendo como foco a área das Ciências Médicas. A palestra será realizada pelo Prof. Dr. Rafael Roesler, Federal University of Rio Grande do Sul - Department of Pharmacology, Institute for Basic Health Sciences, and Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA). Ele colocará em pauta a temática “Novel Epigenetic Targets in Pediatric Brain Tumors".
O bem-sucedido programa Tübingen Science Bridge - Brazil, lançado em abril de 2022, em cooperação com universidades parceiras do Brasil, ganha um novo capítulo. Em sua nova fase, o programa agregará outros países da América Latina, incluindo inicialmente Argentina, Chile, Peru, Colômbia e México. A partir de então, o programa ganha mais uma edição: Tübingen Science Bridge - Latin America.
Assim como anteriormente, o programa contribuirá para a internacionalização da ciência e da pesquisa. Cientistas de diversas instituições parceiras apresentam seus últimos dados de pesquisa, promovendo um ambiente integrado e construtivo da ciência e, ainda, disseminando o conhecimento global.
As palestras on-line do Tübingen Science Bridge são destinadas a professores e pesquisadores científicos, alunos de pós-graduação, como também para o público em geral. Os webinars acontecem em inglês na plataforma ZOOM para permitir a discussão e interação.
Faça sua inscrição aqui: https://bit.ly/TSB-november
Mais informações sobre o e Tübingen Science Bridge (agenda, palestras e links de inscrições): https://bit.ly/TSB-Agenda2022
***Deutsche Version ***
Das nächste Online-Seminar im Rahmen des Programms Tübingen Science Bridge – Brazil wird am 09. November um 03:30 pm MEZ (11:30 am BRT) stattfinden. Der Vortrag ordnet sich in den Bereich Gesundheitswissenschaft ein und wird von Prof. Dr. Rafael Roesler, Federal University of Rio Grande do Sul - Department of Pharmacology, Institute for Basic Health Sciences, and Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA) gehalten. Das Thema lautet "Novel Epigenetic Targets in Pediatric Brain Tumors".
Das Baden-Württembergische Brasilien- und Lateinamerika-Zentrum dehnt das erfolgreiche Programm Tübingen Science Bridge – Brazil, das im April 2022 in Kooperation mit Partneruniversitäten in Brasilien startete, auf weitere Länder in Lateinamerika aus. Der Ausbau umfasst zunächst die Tübinger Partneruniversitäten in Argentinien, Chile, Peru, Kolumbien und Mexiko. Ab jetzt heißt das Programm deshalb Tübingen Science Bridge - Latin America.
Wie zuvor will das Programm einen Beitrag zur Internationalisierung von Wissenschaft und Forschung leisten. Hochkarätige Wissenschaftler:innen der verschiedenen Partnerinstitutionen präsentieren ihre neuesten Forschungsergebnisse und tragen damit zu einer gemeinsamen und konstruktiven Basis für die wissenschaftliche Zusammenarbeit bei.
Die Vorträge der Tübingen Science Bridge richten sich besonders an Hochschullehrer:innen und (Nachwuchs-)Wissenschaftler:innen, sowie an ein allgemeines wissenschaftlich interessiertes Publikum.
Die Veranstaltungen finden auf Englisch über die Plattform ZOOM statt, um eine Diskussion und Interaktion zu ermöglichen.
Registrieren Sie sich hier: https://bit.ly/TSB-november
Mehr Information über das Programm Tübingen Science Bridge: Die Veranstaltungsdaten für die nächsten Monate sowie allgemeine Hinweise finden Sie hier: https://bit.ly/TSB-Agenda2022